Floatz logo

HYDROMORPHON

Alpha-1 Antitrypsin Deficiency

Arrowhead PharmaceuticalsSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Alpha-1 Antitrypsin Deficiency cohort.

Asset / SponsorPhaseRating
Wve-006
Wave Life Sciences USA, Inc.
Phase 1/2B
Acetylsalicylic Acid
Columbia University
Phase 2B
Kamada-Aat For Inhalation
Kamada, Ltd.
Phase 2B
vx-864
Vertex Pharmaceuticals Incorporated
Phase 2CCC
vx-668
Vertex Pharmaceuticals Incorporated
Phase 1CC

View all 16 →

Same molecule, other indications

HYDROMORPHON is also rated in:

substance-related disorderDormant
BBB
Indicative ·
74 / 100
View asset →
Low Back PainDormant
BBB
Indicative ·
72 / 100
View asset →
Analgesics, OpioidDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →